<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03484234</url>
  </required_header>
  <id_info>
    <org_study_id>AMCCV2018-05</org_study_id>
    <nct_id>NCT03484234</nct_id>
  </id_info>
  <brief_title>Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-VII: Sirolimus-eluting (Ultimaster) vs. Everolimus-Eluting Stents (Xience)</brief_title>
  <acronym>LONG-DES VII</acronym>
  <official_title>A Multi-center, Randomized, Study to Compare the Effectiveness of Sirolimus-eluting Stent (Ultimaster Stent) or Everolimus-eluting Stent (XIience Alpine Stent) for Long Coronary Lesions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seung-Jung Park</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CardioVascular Research Foundation, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares angiographic and clinical outcomes in patients with long coronary lesions
      treated with sirolimus-eluting stent (Ultimaster stent) or everolimus-eluting stent (Xience
      Alpine stent). The study uses a randomized, multicenter, controlled design approach.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 30, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-segment late luminal loss</measure>
    <time_frame>13-month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All death</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction (MI)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of death or MI</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of cardiac death or MI</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization (ischemia-driven and clinically-driven)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization (ischemia-driven and clinically-driven)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target-vessel failure</measure>
    <time_frame>1 year</time_frame>
    <description>death from any cause, myocardial infarction, and ischemic-driven target-vessel revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent late loss</measure>
    <time_frame>13-month</time_frame>
    <description>In-stent late loss at 13-month angiographic follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent and in-segment restenosis</measure>
    <time_frame>13-month</time_frame>
    <description>In-stent and in-segment restenosis at 13-month angiographic follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic pattern of restenosis</measure>
    <time_frame>13-month</time_frame>
    <description>Angiographic pattern of restenosis at 13 -month angiographic follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of intimal hyperplasia</measure>
    <time_frame>13-month</time_frame>
    <description>Volume of intimal hyperplasia at 13-month IVUS follow-up (sub-study)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of late stent malapposition</measure>
    <time_frame>13-month</time_frame>
    <description>Incidence of late stent malapposition at 13-month IVUS follow-up (sub-study)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success</measure>
    <time_frame>5 days</time_frame>
    <description>Procedural success defined as achievement of a final diameter stenosis of &lt;30% by QCA using any percutaneous method, without the occurrence of death, Q wave MI, or repeat revascularization of the target lesion during the hospital stay.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Stenosis</condition>
  <arm_group>
    <arm_group_label>Ultimaster stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Xience alpine stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ultimaster stent</intervention_name>
    <description>Percutaneous coronary intervention with Ultimaster stent for long lesion</description>
    <arm_group_label>Ultimaster stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xience alpine stent</intervention_name>
    <description>Percutaneous coronary intervention with Xience alpine stent for long lesion</description>
    <arm_group_label>Xience alpine stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patient must be at least 19 years of age.

          2. Significant native coronary artery stenosis (&gt;50% by visual estimate) with lesion
             length of more than 25mm, which requiring at long stent placement without intervening
             normal segment.

          3. Patients with silent ischemia, stable or unstable angina pectoris, ad Non-ST-elevation
             myocardial infarction (NSTEMI)

          4. The patient or guardian agrees to the study protocol and the schedule of clinical and
             angiographic follow-up, and provides informed, written consent, as approved by the
             appropriate Institutional Review Board/Ethical Committee of the respective clinical
             site.

        Exclusion Criteria:

          1. Any contraindication to any of the following medications: aspirin, heparin,
             clopidogrel, stainless steel, contrast agents, sirolimus, or everolimus

          2. An elective surgical procedure is planned that would necessitate interruption of
             antiplatelet drugs during the first 6 months post enrollment.

          3. Acute ST-segment-elevation MI or cardiogenic shock

          4. Terminal illness with life expectancy &lt;1 year

          5. In-stent restenosis at target vessel (either bare metal stent or drug-eluting stent
             segment). However, non-target vessel ISR is permitted.

          6. Patients with EF&lt;30%.

          7. Serum creatinine level â‰¥ 2.0mg/dL or dependence on dialysis.

          8. Patients with left main stem stenosis (&gt;50% by visual estimate)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Seung-jung Park, MD</last_name>
    <phone>82230104812</phone>
    <email>sjpark@amc.seoul.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jung-hee Ham, RN</last_name>
    <email>cvcrc5@amc.seoul.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2018</study_first_submitted>
  <study_first_submitted_qc>March 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2018</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Seung-Jung Park</investigator_full_name>
    <investigator_title>Professor, Division of Cardiology</investigator_title>
  </responsible_party>
  <keyword>Drug eluting stent</keyword>
  <keyword>everolimus eluting stent</keyword>
  <keyword>sirolimus eluting stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

